Effectiveness of the Soluble Form of the Interleukin-1 Receptor Accessory Protein as an Inhibitor of Interleukin-1 in Collagen-Induced Arthritis

Arthritis and Rheumatism

Volumn 48, Issue 10, 2003, Pages 2949-2958

  Smeets, R L ^a   Van de Loo, F A J ^a,d   Joosten, L A B ^a   Arntz, O J ^a   Bennink, M B ^a   Loesberg, W A ^a   Dmitriev, I P ^b   Curiel, D T ^b   Martin, M U ^c   Van den Berg, W B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTHRITIS; ARTICLE; BIOASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; HISTOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; ARTHRITIS, EXPERIMENTAL; CLONING, MOLECULAR; GENE EXPRESSION; GENE THERAPY; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; KNEE JOINT; MALE; MICE; MICE, INBRED DBA; NF-KAPPA B; NIH 3T3 CELLS; PROTEINS; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 0142040402     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11234     Document Type: Article

References (31)

1. Neumann D, Kollewe C, Martin MU, Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol 2000;165:3350-7.
2. Attur MG, Dave MN, Leung MY, Cipolletta C, Meseck M, Woo SL, et al. Functional genomic analysis of type II IL-1β decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol 2002;168:2001-10.
3. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995;270:13757-65.
4. Liege S, Laye S, Li K, Moze E, Neveu PJ. Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta. J Neuroimmunol 2000;110:134-9.
5. Casadio R, Frigimelica E, Bossu P, Neumann D, Martin MU, Tagliabue A, et al. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1R(I) complex. FEBS Lett 2001;499:65-8.
6. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem 1997;272:7727-31.
7. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998;273:12203-9.
8. Cao Z, Henzel WJ, Gao X. IRAK: A kinase associated with the interleukin-1 receptor. Science 1996;271:1128-31.
9. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996;383:443-6.
10. Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 2000;164:5277-86.
11. Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor a, and interleukin-6 in cartilage proteoglycan metabolism and destruction: Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
12. Smith RJ, Chin JE, Sam LM, Justen JM. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991;34:78-83.
13. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993;36:1305-14.
14. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo FA, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997;40:893-900.
15. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-tumor necrosis α, anti-interleukin-1α /β, and interleukin-1 receptor antagonist. Arthritis Rheum 1996;39:797-809.
16. Bakker AC, van de Loo FA, Joosten LA, Arntz OJ, Varley AW, Munford RS, et al. C3-Tat/HIV-regulated intraarticular human interleukin-1 receptor antagonist gene therapy results in efficient inhibition of collagen-induced arthritis superior to cytomegalovirus-regulated expression of the same transgene. Arthritis Rheum 2002;46:1661-70.
17. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996;70:4805-10.
18. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
19. Erbacher P. Methods for adenovirus-mediated gene transfer to airway epithelium. In: Robbins PD, editor. Methods in molecular medicine, gene therapy protocols. Totawa, NY: Humana Press; 1997. p. 169-84.
20. Van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis: a study in interleukin-6-deficient mice. Am J Pathol 1997;15:177-91.
21. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
22. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838-46.
23. Wesche H, Resch K, Martin MU. Effects of IL-1 receptor accessory protein on IL-1 binding. FEBS Lett 1998;429:303-6.
24. Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol 1997;27:262-7.
25. Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998;161:5614-20.
26. Van Lent PL, van den Bersselaar L, Grutters GJ, van den Berg WB. Fate of antigen after intravenous and intraarticular injection into mice: role of molecular weight and charge. J Rheumatol 1989;16:1295-303.
27. Huang J, Gao X, Li S, Cao Z. Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A 1997;94:12829-32.
28. Malinowsky D, Lundkvist J, Laye S, Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 1998;429:299-302.
29. Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998;16:6871-7.
30. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003;18:87-96.
31. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A 1995;92:1714-8.